Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | UBE2M | P61081 | 1/20 | 0.40 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2421117 | 0.86 | POLB (0.50) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL2416404 | 0.86 | POLB (0.46) | POLBKMT2ANPC1RAB9AL3MBTL1 | |
| SCHEMBL2417022 | 0.86 | LMNA (0.45) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL2423078 | 0.83 | POLB (0.46) | POLBKMT2AMEN1NPC1HPGD | |
| SCHEMBL2420282 | 0.79 | HTT (0.40) | ALDH1A1 | |
| SCHEMBL2423114 | 0.77 | ALDH1A1 (0.54) | POLBKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL2420488 | 0.75 | GAA (0.52) | POLBKMT2AMEN1NPC1RAB9A | |
| SCHEMBL2420525 | 0.74 | ALDH1A1 (0.48) | POLBKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL2415512 | 0.73 | POLB (0.36) | POLBKMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL2416409 | 0.72 | ALDH1A1 (0.47) | POLBKMT2AMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017772-B2 | Substituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain | GRUENENTHAL GMBH (DE) | 2011-09-13 | — | — | US | claimed |
| US-20100004252-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND/OR INHIBITION OF PAIN | GRUENENTHAL GMBH (DE) | 2010-01-07 | — | — | US | claimed |
| US-7625900-B2 | Sutstituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain | GRUENENTHAL GMBH (DE) | 2009-12-01 | — | — | US | claimed |
| EP-2112993-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS HAVING AFFINITY WITH THE KCNQ2/3 K+ CHANNEL AND USE THEREOF IN MEDICAMENTS | Grünenthal GmbH (DE) | 2009-11-04 | — | — | EP | claimed |
| CN-101547925-A | For KCNQ2/3K+Substituted tetrahydropyrrolopyrazine compounds with channel affinity and their use in medicine | GRUENENTHAL GMBH (DE) | 2009-09-30 | — | — | CN | claimed |
| US-20080167315-A1 | Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain | GRUENENTHAL GMBH (DE) | 2008-07-10 | — | — | US | claimed |
| WO-2008046582-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS HAVING AFFINITY WITH THE KCNQ2/3 K+ CHANNEL AND USE THEREOF IN MEDICAMENTS | Grünenthal GmbH (DE) | 2008-04-24 | — | — | WO | claimed |
| US-8017772-B2 | Substituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain | GRUENENTHAL GMBH (DE) | 2011-09-13 | — | — | US | disclosed |
| US-20100004252-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND/OR INHIBITION OF PAIN | GRUENENTHAL GMBH (DE) | 2010-01-07 | — | — | US | disclosed |
| US-7625900-B2 | Sutstituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain | GRUENENTHAL GMBH (DE) | 2009-12-01 | — | — | US | disclosed |
| EP-2112993-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS HAVING AFFINITY WITH THE KCNQ2/3 K+ CHANNEL AND USE THEREOF IN MEDICAMENTS | Grünenthal GmbH (DE) | 2009-11-04 | — | — | EP | disclosed |
| CN-101547925-A | For KCNQ2/3K+Substituted tetrahydropyrrolopyrazine compounds with channel affinity and their use in medicine | GRUENENTHAL GMBH (DE) | 2009-09-30 | — | — | CN | disclosed |
| US-20080167315-A1 | Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain | GRUENENTHAL GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| WO-2008046582-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS HAVING AFFINITY WITH THE KCNQ2/3 K+ CHANNEL AND USE THEREOF IN MEDICAMENTS | Grünenthal GmbH (DE) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004252-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND/OR INHIBITION OF PAIN | KCNQ2, KCNQ1, KCNJ2 | POLB 4056/4885KMT2A 770/4885MEN1 3558/4885 |
| US-20080167315-A1 | Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain | KCNQ2, KCNQ1, KCNJ2 | POLB 4056/4885KMT2A 770/4885MEN1 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.